Assess whether earnings quality supports the bid price (d665f8)

Situation

A health-system acquiring a specialty practice cannot treat a founder who will not sign a non-compete as color commentary on QoE add-backs the seller marked 'normalized'. Buy-side QoE lead must close earnings quality supports the from that extract under M&A Due Diligence / Legal, IP, and Regulatory.

Decision

Buy-side QoE lead in a health-system acquiring a specialty practice must choose Proceed / Reprice / Walk / Hold using QoE add-backs the seller marked 'normalized' after a founder who will not sign a non-compete.

Hypotheses to test

• QoE add-backs the seller marked 'normalized' reads as Proceed once a founder who will not sign a non-compete is lined up to the same M&A Due Diligence population.
• QoE add-backs the seller marked 'normalized' is closer to Reprice after a founder who will not sign a non-compete; Proceed would over-claim this Legal, IP, and Regulatory extract.
• Walk is still live in QoE add-backs the seller marked 'normalized' for buy-side QoE lead in a health-system acquiring a specialty practice.
• QoE add-backs the seller marked 'normalized' is missing the fact buy-side QoE lead needs after a founder who will not sign a non-compete; stop this M&A Due Diligence close.

Analysis required

• Tie quality-of-earnings, working-capital, and contingent items in QoE add-backs the seller marked 'normalized' to earnings quality supports the.
• Name the document buy-side QoE lead still needs before signing.
• Test whether a founder who will not sign a non-compete is a diligence gap, a price chip, or a walk-away.
• For this M&A Due Diligence Legal, IP, and Regulatory file, read QoE add-backs the seller marked 'normalized' against a founder who will not sign a non-compete and write the one fact that would move earnings quality supports the for buy-side QoE lead.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (QoE add-backs the seller marked 'normalized' after a founder who will not sign a non-compete). Lead with the M&A Due Diligence option QoE add-backs the seller marked 'normalized' can support after a founder who will not sign a non-compete, then the two facts that force it, then the Monday action for buy-side QoE lead in a health-system acquiring a specialty practice.